DekaBank Deutsche Girozentrale
AVIR icon

DekaBank Deutsche Girozentrale’s Atea Pharmaceuticals AVIR Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-61,900
Closed -$546K – 1339
2021
Q4 		$546K Buy
+61,900
New +$965K ﹤0.01% 1079

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DekaBank Deutsche Girozentrale's AVIR Position: Q1 2022 in Review

DekaBank Deutsche Girozentrale sold out of Atea Pharmaceuticals (AVIR) in Q1 2022, closing a stake of 61,900 shares — an estimated $546K sold.

DekaBank Deutsche Girozentrale first reported a position in AVIR in Q4 2021 and held it in 1 quarter. The position peaked at $546K in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2022.

  • DekaBank Deutsche Girozentrale reported no remaining Atea Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 61,900 Atea Pharmaceuticals shares in Q1 2022, an estimated $546K.
  • DekaBank Deutsche Girozentrale first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • DekaBank Deutsche Girozentrale's Atea Pharmaceuticals position peaked at $546K in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2022, filed 28 Apr 2022.